Navigation Links
Aeterna Zentaris Reports First Quarter 2010 Financial and Operating Results
Date:5/13/2010

All amounts are in U.S. dollars

QUEBEC CITY, May 13 /PRNewswire-FirstCall/ - Aeterna Zentaris Inc. ( AEZS, TSX: AEZ) ("the Company"), a late-stage drug development company specialized in oncology and endocrinology, today reported financial and operating results as at and for the three months ended March 31, 2010.

First Quarter 2010 Highlights

    - January 25, 2010: Updated results of a Phase 2 study related to the use
      of perifosine in the treatment of advanced metastatic colon cancer
      showing a statistically significant benefit in survival, including
      5 FU-refractory patients.

    - January 29, 2010: Publication in the February 2010 issue of the Journal
      of Clinical Cancer Research of positive Phase 2 results for perifosine
      as a single agent for the treatment of advanced Waldenstrom's
      macroglobulinemia.

    - February 3, 2010: Special Protocol Assessment ("SPA") granted by the
      United States Food and Drug Administration ("FDA") for the Phase 3
      trial of perifosine in combination with capecitabine (Xeloda(R)) in
      refractory advanced colorectal cancer. The trial is to be conducted by
      Keryx Biopharmaceuticals, Inc. ("Keryx") ( KERX), Aeterna
      Zentaris' partner and licensee for perifosine in North America.

    - March 1, 2010: Disclosure that the Committee for Orphan Medicinal
      Products of the European Medicines Agency ("EMA") had issued a positive
      opinion for orphan medicinal product designation for perifosine for the
      treatment of multiple myeloma.

Subsequent to Quarter-End

    - April 5, 2010: Perifosine receives FDA Fast Track Designation for the
      Phase 3 X-PECT (Xeloda(R) + Perifosine Evaluation in Colorectal cancer
      Treatment) registration trial.

    - April 8, 2010: Initiation 
'/>"/>
SOURCE AETERNA ZENTARIS INC.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Aeterna Zentaris: FDA Approves Investigational New Drug (IND) Application for Doxorubicin Targeted Conjugate Compound, AEZS-108, in Bladder Cancer
2. Aeterna Zentaris Receives Orphan-Drug Designation from the FDA for AEZS-108 in Ovarian Cancer
3. AEterna Zentaris Announces Termination of Agreement with sanofi-aventis U.S. for the Development, Commercialization and Licensing of Cetrorelix in Benign Prostatic Hyperplasia
4. AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma
5. AEterna Zentaris Announces Appointment of New Board Member
6. AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology
7. AEterna Zentaris Announces Results from its European Phase 3 Study with Cetrorelix in Benign Prostatic Hyperplasia
8. AEterna Zentaris Anti-Cancer Compound, Perifosine (KRX-0401), Receives FDA Fast Track Designation for the Treatment of Relapsed/Refractory Multiple Myeloma
9. AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer
10. AEterna Zentaris Receives US$5.5 Million from Institutional Investors
11. AEterna Zentaris to Raise US$5.5 Million from Institutional Investors at US$1.20 Per Share
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/1/2015)... Shimadzu Corporation announced that its fully automated ... UC) received the Pittcon Editors’ Gold award at ... Applied Spectroscopy (Pittcon) held in New Orleans, LA ... Pittcon Editors’ Awards recognize the most innovative products ... on votes by the media corps. Editors awarded ...
(Date:4/1/2015)... , April 1, 2015  VLP Therapeutics, LLC. ... focusing on the research and development of therapeutic and ... a novel and proprietary vaccine technology, today announced that it ... of Tropical Medicine at Nagasaki ... will facilitate VLP,s research and development of dengue vaccine ...
(Date:4/1/2015)... , April 1, 2015 /PRNewswire/ - Portage Biotech ... PBT.U), is pleased to announce that Biohaven Pharmaceutical ... equity, has entered into an agreement with inVentiv ... clinical trial with their lead compound (BHV-0223). ... and development of clinical stage neuroscience compounds targeting ...
(Date:4/1/2015)... Research and Markets ( http://www.researchandmarkets.com/research/8dzk58/blood_screening ... "Blood Screening Market by Technology (Nucleic Acid Amplification ... Sequencing, Western Blotting), Product (Instrument, Reagent) & End ... " report to their offering. ... $2.55 billion by 2019 from $1.5 billion in ...
Breaking Biology Technology:Shimadzu Nexera UC Recognized at Pittcon 2015 with Editors’ Gold Award 2VLP Therapeutics Enters Collaboration with Institute of Tropical Medicine, Nagasaki University 2VLP Therapeutics Enters Collaboration with Institute of Tropical Medicine, Nagasaki University 3Portage's Biohaven Announces Agreement with inVentiv Health 2Portage's Biohaven Announces Agreement with inVentiv Health 3Global Blood Screening (Nucleic Acid Amplification Test, ELISA, Rapid Test, Chemiluminescence Immunoassay, Next Generation Sequencing, Western Blotting) Market 2015-2019 2Global Blood Screening (Nucleic Acid Amplification Test, ELISA, Rapid Test, Chemiluminescence Immunoassay, Next Generation Sequencing, Western Blotting) Market 2015-2019 3
... MEDFORD/SOMERVILLE, Mass. -- Promising research on superconducting materials, near ... Tufts University,s School of Engineering early career awards from ... The awards are among the most prestigious honors given ... at the early stages of their careers, when many ...
... March 23 The Superior Court of Pennsylvania has reinstated an appeal filed by ... been dismissed by an order from the same court on February 18, 2010 . The Superior Court also ... ... , ...
... - and authorities on the track of illicit alcohol ... hand. Measurement experts have unveiled a portable device to ... almost anywhere. Published in the open access Chemistry ... is just as accurate, and more sophisticated, than widely ...
Cached Biology Technology:3 Tufts engineering faculty earn prestigious national awards for promising research 23 Tufts engineering faculty earn prestigious national awards for promising research 3UPDATE: Appeal of Lawsuit by Former Chief Executive Officer- Reinstated; and Sanctions Order Vacated 2How strong is your booze? 2
(Date:3/18/2015)... March 18, 2015 As mobile payments ... revolutionary smart wallets and apps continue to be introduced into ... in the mobile payment industry in focus today are:  NXT-ID, ... (NYSE: BABA ), Apple Inc. (NASDAQ: ... Facebook Inc. (NASDAQ: FB ) NXT-ID, ...
(Date:3/16/2015)... 16, 2015 Between 16 ... present groundbreaking innovations in biometric identification at the ... .      (Photo: http://photos.prnewswire.com/prnh/20150316/735333 ... is well at the forefront: the company,s all ... in Germany . BiometricGate is ...
(Date:3/12/2015)... March 12, 2015 WHEN:Tuesday, March 17, 2015 ... http://bit.ly/1G7Os0L . SPEAKERS: , Frost & Sullivan ... http://photos.prnewswire.com/prnh/20150311/181111 Biometric companies must ... in several different markets and industries. This is ... an uptrend. Join Frost & ...
Breaking Biology News(10 mins):Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 2Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 3Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 4Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 5Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 6DERMALOG Presents its Latest Biometric Innovations at the Hannover CeBIT Exhibition, 16 - 20 March 2015 2DERMALOG Presents its Latest Biometric Innovations at the Hannover CeBIT Exhibition, 16 - 20 March 2015 3Biometrics Key to Future Growth in Healthcare, Retail and Financial Markets 2Biometrics Key to Future Growth in Healthcare, Retail and Financial Markets 3
... RIVERSIDE, Calif. ( www.ucr.edu ) -- A team led ... Bourns College of Engineering has made a discovery in ... from kill viruses to increase storage capacity of DVDs. ... data processing, information storage and biology. Their applications have ...
... 19th conference of the International Society for Sexually Transmitted ... in Quebec City, Canada. The world,s foremost conference ... 1,200 scientists from every continent to discuss the most ... and treatment; emerging threats in bacterial STDs; major intervention ...
... Spanish . The last of seven cotton ... a major 4-year cotton gin dust sampling project draws to ... project to intensively sample emissions from seven cotton gins across ... Research Service (ARS) Cotton Production and Processing Research Unit in ...
Cached Biology News:New laser technology could kill viruses and improve DVDs 2ARS and cooperators study cotton gin dust emissions 2
...
...
... rapidly and reliably amplify unknown genomic DNA ... provides hassle-free, ready-to use components, at an ... provided in each kit. The Genome Walking ... localized cloning of genomic DNA, isolating promoter ...
N,N'-Methylene-bis-acrylamide, Ultra Pure...
Biology Products: